DiaMedica (TSX VENTURE:DMA) has successfully completed cGMP manufacturing of
DM-199 to be utilized in upcoming clinical trials. Additionally, the Company has
successfully completed GLP toxicology studies in non-human primates and rat
models, and has demonstrated DM-199 to be safe and well-tolerated in repeated
high dose administrations.


"Successful cGMP manufacture is a major development milestone for our DM-199
program and we are working on our regulatory package for a Phase I/II clinical
trial which includes Type 2 diabetic patients. The trial design will also allow
us to enter Phase 2 trials for multiple indications," stated Rick Pauls,
Chairman & CEO of DiaMedica. "Achieving a proprietary, commercially viable
manufacturing process of DM-199 and a comprehensive patent position including
composition of matter, methods of uses and route of delivery should create a
significant barrier to entry for any follow-on competitors."


The large-scale proprietary cGMP manufacturing process resulted in a high yield
batch of DM-199 to be used in upcoming clinical trials. The GLP preclinical
toxicology studies demonstrate DM-199 is safe and well tolerated at doses at
least 25 fold higher than the expected human therapeutic dose over 28-days of
repeated-dose and cardiovascular safety studies in non-human primates and rats.
The daily administration of DM-199 was safe and well tolerated with no serious
adverse events or any other tissue toxicity. Furthermore, DM-199 showed no
negative cardiovascular treatment-related effects, including heart rate or ECG
intervals, which are important safety attributes for any Type 2 diabetes
therapy. Based on toxicology results, doses previously reported for chronic Type
2 diabetes pre-clinical studies could be increased by at least four-hundred
(400) fold, suggesting a large therapeutic window.


"The pre-clinical GLP toxicology studies have further demonstrated a good safety
profile of DM-199," noted Mark Robbins, Vice President of Clinical and
Regulatory Affairs. "These results support moving forward into the clinic in the
near term to assess safety and tolerability in healthy volunteers and efficacy
in Type 2 diabetic patients."


About DiaMedica 

DiaMedica Inc. (TSX VENTURE:DMA) is biotechnology company developing
first-in-class treatments for the treatment of diabetes. DiaMedica's lead
compound, DM-199, a recombinant human protein for the treatment of both Type 1
and Type 2 diabetes and their complications. The Company is also developing the
first therapeutic GPCR agonist monoclonal antibody, DM-204, for the treatment of
Type 2 diabetes and cardiovascular disease. DiaMedica's shares trade on the
Toronto Stock Exchange Venture (TSX VENTURE:DMA). For more information please
visit www.diamedica.com.


FORWARD-LOOKING STATEMENTS 

The statements made in this press release that are not historical facts contain
forward-looking information that involves risk and uncertainties. All
statements, other than statements of historical facts, which address DiaMedica's
expectations, should be considered forward-looking statements. Such statements
are based on management's exercise of business judgment as well as assumptions
made by and information currently available to management. When used in this
document, the words "may", "will", "anticipate", "believe", "estimate",
"expect", "intend" and words of similar import, are intended to identify any
forward-looking statements. You should not place undue reliance on these
forward-looking statements. These statements reflect a current view of future
events and are subject to certain risks and uncertainties as contained in the
Corporation's filings with Canadian securities regulatory authorities. Should
one or more of these risks or uncertainties materialize, or should underlying
assumptions prove incorrect, actual results could differ materially from those
anticipated in these forward-looking statements. The Corporation undertakes no
obligation, and does not intend, to update, revise or otherwise publicly release
any revisions to these forward-looking statements to reflect events or
circumstances after the date hereof, or to reflect the occurrence of any
unanticipated events. Although management believes that expectations are based
on reasonable assumptions, no assurance can be given that these expectations
will materialize.


FOR FURTHER INFORMATION PLEASE CONTACT: 
DiaMedica Inc.
Rick Pauls
Chairman & CEO
763-710-4455
info@diamedica.com
DiaMedica Inc. (TSXV:DMA)
Historical Stock Chart
From Jun 2024 to Jul 2024 Click Here for more DiaMedica Inc. Charts.
DiaMedica Inc. (TSXV:DMA)
Historical Stock Chart
From Jul 2023 to Jul 2024 Click Here for more DiaMedica Inc. Charts.